Jordana Fein
Retina Specialist · Manassas, VANPI 1841463098
Payments from drug & device makers
Across 1,047 payments — averaging $1824.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$550K
- Bayer$377K
- Regeneron$316K
- AstraZeneca$219K
- Regeneron Healthcare Solutions, Inc.$212K
- Ocular Therapeutix, Inc.$111K
- plus $125K from 20 others
Across 5 payments — averaging $1847.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$9K
What the payments were for
- Consulting fees$107,25226%
- Speaking & faculty fees$267,31465%
- Travel & lodging$25,9576%
- Food & beverage$11,0783%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 297 | $550,402 |
| Bayer | 247 | $377,206 |
| Regeneron | 128 | $315,900 |
| AstraZeneca | 3 | $219,284 |
| Regeneron Healthcare Solutions, Inc. | 174 | $212,237 |
| Ocular Therapeutix, Inc. | 15 | $110,667 |
| Kyowa Kirin, Inc. | 21 | $54,608 |
| Genentech USA, Inc. | 54 | $52,432 |
| Harrow Eye, LLC | 5 | $5,669 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $3,858 |
| Bausch & Lomb Americas Inc. | 16 | $3,751 |
| Cardinal Health 108 LLC | 1 | $1,575 |
| Notal Vision, Inc. | 25 | $859 |
| AbbVie(2 entities) | 25 | $638 |
| Novartis | 8 | $324 |
| Astellas Pharma US Inc | 5 | $168 |
| Biotissue Holdings Inc. | 1 | $137 |
| Dompe US, Inc. | 1 | $125 |
| Eyepoint US, Inc. | 6 | $123 |
| Alcon | 1 | $115 |
| Alimera Sciences, Inc. | 2 | $51 |
| Neurotech Pharmaceuticals, Inc. | 1 | $43 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Astellas Pharma Global Development | 1 | $23 |
| Vyera Pharmaceuticals, LLC | 1 | $17 |
| Genentech, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,910,261 in reported general payments places this provider in the 95th percentile of 41 retina specialist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 52 | $2,126 |
| Ofloxacin | 28 | $376 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $217 |
| Latanoprost | 21 | $174 |
| Timolol Maleate | 18 | $49 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Manassas
- Andy HayManassas$19
- Alexander MelamudFairfax$1.1M
- Joaquin TosiVirginia Beach$334K
- Thomas JohnsonFredericksburg$240K
- Anna MackinRoanoke$151K
- Mohit NandaCharlottesville$31K
- Muge KesenMc Lean$30K
- Dal ChunVienna$30K
- Jon AdlebergChesapeake$21K
- Kori ElkinsPortsmouth$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.